BTK and B-cell chronic lymphocytic leukemia: Over the past decade, BTK inhibitors have become an increasingly popular alternative to chemotherapy-based regimens, particularly in patients who suffer from chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) [55,56].